Stock Symbol OZSC
WEST PALM BEACH, Fla., Oct. 11, 2018 (GLOBE NEWSWIRE) -- Ozop Surgical Corp. (OTC “OZSC”), a provider of premium surgical devices in the rapidly growing field of minimally invasive surgery, today announced that The Depository Trust Company (the "DTC") has approved its common stock for DWAC/FAST transfer through the Company's Transfer Agent, Vstock Transfer, LLC. This newly approved stock transfer capability will enable Ozop shareholders to transfer their shares of OZSC stock electronically after buying or selling on the open market, without the extra expense and delay associated with the processing and transfer of physical share certificates.
Companies approved for DWAC/FAST electronic transfers often experience higher trading volumes in their stock given the additional accessibility and availability of shares for trading. "We are pleased to announce another shareholder-friendly step in our evolution as a public company. DWAC transfer eligibility enables our shareholders to maintain the highest levels of efficiency, accountability and compliance standards for their trading activities in our shares through the best and most up-to-date electronic securities trading platforms being used today," stated Michael Chermak, CEO of Ozop.
About DWAC/FAST
DWAC allows participants to instruct DTC regarding deposit and withdrawal transactions being made directly via a FAST transfer agent. The FAST system eliminates the movement of physical share certificates for transfers of securities registered in the name of DTC's nominee, Cede & Co., on the transfer agent's books. DTC and its FAST transfer agents reconcile the results of participants' deposit and withdrawal activities electronically on a daily basis.
About Ozop Surgical Corp.
Ozop Surgical Corp. (www.ozopsurgical.com) invents, designs, develops, manufactures and globally distributes innovative endoscopic instruments, surgical implants, instrumentation, devices and related technologies, focused on spine, neurological and pain management procedures and specialties. Our focus is on economically disrupting the market with clinically equivalent or superior existing and new products resulting in immediate and significant savings for providers, payors and consumers. For more information please visit www.ozopsurgical.com.
Safe Harbor Statement
This news release contains statements that involve expectations, plans or intentions (such as those relating to future business or financial results) and other factors discussed from time to time in the Company's Securities and Exchange Commission filings. These statements are forward-looking and are subject to risks and uncertainties, so actual results may vary materially. You can identify these forward-looking statements by words such as "may," "should," "expect," "anticipate," "believe," "estimate," "intend," "plan" and other similar expressions. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of certain factors not within the control of the company. The company cautions readers not to place undue reliance on any such forward-looking statements, which speak only as of the date made. The company disclaims any obligation subsequently to revise any forward-looking statements to reflect events or circumstances after the date of such statements or to reflect the occurrence of anticipated or unanticipated events.
Investor Relations:
Ted Haberfield
President
MZ Group - MZ North America
(760) 755-2716
thaberfield@mzgroup.us
www.mzgroup.us